SCHEMBL221563

SCHEMBL221563

CCCCC/C=C\C/C=C\CCCCCCCCO[C@H]1C[C@H](CN(C)C)C[C@H]1OCCCCCCCC/C=C\C/C=C\CCCCC

nearest known ligand 0.50

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.40
CNR1 P21554 1/20 0.40
CNR2 P34972 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL199145 1.00 ALDH1A1 (0.40) ALDH1A1CNR1CNR2
SCHEMBL19525638 1.00 ALDH1A1 (0.40) ALDH1A1CNR1CNR2
SCHEMBL200528 0.92 FAAH (0.38) ALDH1A1CNR1CNR2
SCHEMBL198246 0.92 FAAH (0.38) ALDH1A1CNR1CNR2
SCHEMBL131806 0.86 ALDH1A1 (0.44) ALDH1A1CNR1CNR2
SCHEMBL131812 0.86 ALDH1A1 (0.44) ALDH1A1CNR1CNR2
SCHEMBL202180 0.84 ALDH1A1 (0.42) ALDH1A1CNR1CNR2
SCHEMBL202102 0.84 ALDH1A1 (0.42) ALDH1A1CNR1CNR2
SCHEMBL14643018 0.83 ALDH1A1 (0.42) ALDH1A1CNR1CNR2
SCHEMBL10116136 0.83 ALDH1A1 (0.42) ALDH1A1CNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11771715-B2 Circular RNA compositions and methods ORNA THERAPEUTICS, INC. (US) 2023-10-03 US disclosed
US-11766449-B2 Circular RNA compositions and methods ORNA THERAPEUTICS, INC. (US) 2023-09-26 US disclosed
US-20230226096-A1 CIRCULAR RNA COMPOSITIONS AND METHODS ORNA THERAPEUTICS, INC. 2023-07-20 US disclosed
US-11679120-B2 Circular RNA compositions and methods ORNA THERAPEUTICS, INC. (US) 2023-06-20 US disclosed
US-20230058784-A1 CIRCULAR RNA COMPOSITIONS AND METHODS ORNA THERAPEUTICS, INC. 2023-02-23 US disclosed
EP-2512449-B1 METHODS AND COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS UNIV BRITISH COLUMBIA (CA) 2019-08-07 EP disclosed
EP-3238738-A1 NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS Arbutus Biopharma Corporation (CA) 2017-11-01 EP disclosed
US-20160317676-A1 METHODS AND COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS TEKMIRA PHARMACEUTICALS CORPORATION (CA) 2016-11-03 US disclosed
US-8722082-B2 Lipids and compositions for the delivery of therapeutics TEKMIRA PHARMACEUTICALS CORPORATION (CA) 2014-05-13 US disclosed
US-20130017223-A1 METHODS AND COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2013-01-17 US disclosed
US-20120058144-A1 LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS ALNYLAM PHARMACEUTICALS, INC. (US) 2012-03-08 US disclosed
WO-2011075656-A1 METHODS AND COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2011-06-23 WO disclosed
WO-2010054384-A1 LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS ALNYLAM PHARMACEUTICALS, INC. (US) 2010-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11771715-B2 Circular RNA compositions and methods RTCB, HNRNPA1, HNRNPAB ALDH1A1 4484/4885CNR1 4579/4885CNR2 4780/4885
US-20130017223-A1 METHODS AND COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS LIPA, APOB, LIPC ALDH1A1 4338/4885CNR1 3995/4885CNR2 3641/4885
US-20120058144-A1 LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS ABCB4, CETP, SGMS1 ALDH1A1 3777/4885CNR1 2763/4885CNR2 2760/4885
US-20230226096-A1 CIRCULAR RNA COMPOSITIONS AND METHODS RTCB, HNRNPA1, HNRNPAB ALDH1A1 4484/4885CNR1 4579/4885CNR2 4780/4885
US-20160317676-A1 METHODS AND COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS LIPA, APOB, LIPC ALDH1A1 4338/4885CNR1 3995/4885CNR2 3641/4885
US-20230058784-A1 CIRCULAR RNA COMPOSITIONS AND METHODS RTCB, RNGTT, HNRNPAB ALDH1A1 4532/4885CNR1 4492/4885CNR2 4726/4885
US-11679120-B2 Circular RNA compositions and methods RTCB, HNRNPA1, HNRNPAB ALDH1A1 4484/4885CNR1 4579/4885CNR2 4780/4885
US-11766449-B2 Circular RNA compositions and methods RTCB, RNGTT, HNRNPAB ALDH1A1 4532/4885CNR1 4492/4885CNR2 4726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.